Melanoma Cancer section

Melanoma News & Features

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.

Overall Survival Increase for Melanoma Brain Metastases

Overall Survival Increase for Melanoma Brain Metastases

Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.

Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care Providers

Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care Providers

Awareness of personal genetic risk for melanoma may prompt patients to discuss cancer risk with family and health care professionals, and make lifestyle changes.

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.

Melanoma Diagnoses Can Vary Widely Among Pathologists

Melanoma Diagnoses Can Vary Widely Among Pathologists

When researchers sent sample slides to pathologists for review, the assessments varied widely and some pathologists even disagreed with their own initial assessment when retested months later.

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.

Cancer Recurrence Fear Reduced by Novel Psychological Intervention

Cancer Recurrence Fear Reduced by Novel Psychological Intervention

'Conquer Fear' decreased fear among survivors of breast and colorectal cancer and melanoma compared with relaxation techniques.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs